StonvexLoading…
StonvexStonvexStonvexCore line items from CME's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $6.52B | $6.13B | $5.58B | $5.02B |
Operating Income | $4.23B | $3.93B | $3.44B | $3.02B |
Net Income | $4.07B | $3.53B | $3.23B | $2.69B |
EPS (Diluted) | $11.16 | $9.67 | $8.86 | $7.40 |
Total Assets | $198.42B | $137.45B | $129.71B | $174.18B |
Total Liabilities | $169.70B | $110.96B | $102.97B | $147.30B |
Cash & Equivalents | $4.42B | $2.89B | $2.91B | $2.72B |
Free Cash Flow OCF − CapEx | $4.19B | $3.60B | $3.38B | $2.97B |
Shares Outstanding | 360.31M | 359.94M | 359.50M | 359.18M |